Ibrance (palbociclib)

P=N/A, N=1, Completed, Pfizer | Not yet recruiting --> Completed | N=1000 --> 1

P2, N=320, Recruiting, Pfizer | Phase classification: P1 --> P2 | Trial primary completion date: Feb 2028 --> Jul 2029

P1, N=6, Active, not recruiting, West China Hospital | Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> Feb 2027 | Trial primary completion date: Oct 2025 --> Jun 2025

L6565 exhibited homozygous CDKN2A loss with retained Rb expression, rendering tumour cells sensitive to CDK4/CDK6 inhibition via palbociclib. Tumour heterogeneity was reflected in advanced culture methods producing more variability in treatment response. These results highlight the potential of genome-informed therapies in osteosarcoma and the importance of refining culture techniques to enhance translational research and therapeutic outcomes.

P2/3, N=316, Completed, Solti Group | Active, not recruiting --> Completed

Inhibition of mitochondrial complex I further increased ROS levels and enhanced growth inhibition in both endocrine-sensitive and -resistant cell lines and patient-derived xenografts. These findings collectively offer mitochondrial respiration as a therapeutic target in CDK4/6-tolerant persister breast cancer cells to help eradicate residual disease.

A paclitaxel, ifosfamide, and cisplatin-based regimen achieves response rates around 65%...Compared to standard chemotherapy (e.g. cisplatin, 5-FU, ifosfamide, irinotecan), treatment with romidepsin, quisinostat (HDAC inhibitors (i)), palbociclib (CDK4/6i), or 17-AAG and PU-H71 (HSP90i) reduced cell viability, induced apoptosis, and led to G2 / M cell cycle arrest in most PeCa cells. This research underscores the therapeutic potential of using HDAC, CDK4/6, and HSP90 inhibitors for PeCa management and reveals additional promising targets and biomarkers for future strategies.

In India, where patients with BC often present at advanced stages due to late diagnosis and limited access to targeted therapies, Palbociclib offers a well-tolerated and effective treatment option. Real-world data from Indian patients highlight its role in bridging treatment gaps, making personalized therapy more accessible, and aligning treatment strategies with global standards.

P=N/A, N=1500, Recruiting, Pfizer | Active, not recruiting --> Recruiting | Trial completion date: Dec 2025 --> May 2026 | Trial primary completion date: Dec 2025 --> May 2026

P3, N=193, Recruiting, Eli Lilly and Company

Patients who receive CDK4/6 inhibitors for breast cancer experience a low but measurable risk of new-onset atrial arrhythmias. There was no significant difference in new-onset AA risk between agents. Prospective studies are needed to define mechanisms and guide monitoring strategies.

This two-center retrospective study included 203 patients with HR+/HER2- MBC who received first-line CDK4/6 inhibitors (ribociclib or palbociclib) plus endocrine therapy between 2018 and 2024. Although the predictive accuracy of ΔSUVmax alone was modest, the strong survival gradient suggests meaningful prognostic value. Prospective studies with standardized imaging time points and comprehensive metabolic metrics are warranted to define the role of PET-guided treatment adaptation.